blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2415483

EP2415483 - Single dose use of cd20-specific binding molecules [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  18.01.2013
Database last updated on 19.10.2024
Most recent event   Tooltip18.01.2013Application deemed to be withdrawnpublished on 20.02.2013  [2013/08]
Applicant(s)For all designated states
Emergent Product Development Seattle, LLC
2401 Fourth Avenue, Suite 1050
Seattle, Washington 98121 / US
[2012/06]
Inventor(s)01 / Burge, Daniel, Jonathan
23925 SE 25th Court
Sammamish, WA 98075 / US
 [2012/09]
Representative(s)Walker, Ross Thomson, et al
Forresters IP LLP
Skygarden
Erika-Mann-Strasse 11
80636 München / DE
[N/P]
Former [2012/13]Walker, Ross Thomson, et al
Forrester & Boehmert
SkyGarden
Erika-Mann-Strasse 11
80636 München / DE
Former [2012/06]Walker, Ross Thomson
Forrester & Boehmert Pettenkoferstrasse 20-22
80336 München / DE
Application number, filing date11174173.225.07.2006
[2012/06]
Priority number, dateUS20050702498P25.07.2005         Original published format: US 702498 P
US20050702875P27.07.2005         Original published format: US 702875 P
[2012/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2415483
Date:08.02.2012
Language:EN
[2012/06]
Search report(s)(Supplementary) European search report - dispatched on:EP11.01.2012
ClassificationIPC:A61K45/00, A61K39/395, A61P19/02, A61P31/00
[2012/06]
CPC:
C07K16/2887 (EP,US); A61K39/395 (KR); A61K45/06 (EP,US);
A61P1/04 (EP); A61P13/12 (EP); A61P19/02 (EP);
A61P21/00 (EP); A61P25/00 (EP); A61P29/00 (EP);
A61P29/02 (EP); A61P31/00 (EP); A61P35/00 (EP);
A61P37/00 (EP); A61P9/00 (EP); A61K2039/505 (EP,US);
C07K2317/24 (EP,US); C07K2317/52 (EP,US); C07K2317/622 (EP,US);
C07K2317/71 (EP,US); C07K2317/73 (EP,US); C07K2317/732 (EP,US);
C07K2317/734 (EP,US); C07K2319/00 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/06]
TitleGerman:Einzeldosisverwendung CD-20-spezifischer Bindemoleküle[2012/06]
English:Single dose use of cd20-specific binding molecules[2012/06]
French:Utilisation de dose unique de molécules de liaison spécifique au CD20[2012/06]
Examination procedure09.08.2012Application deemed to be withdrawn, date of legal effect  [2013/08]
14.09.2012Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time  [2013/08]
Parent application(s)   TooltipEP06800341.7  / EP1919505
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060800341) is  17.07.2009
Fees paidRenewal fee
14.11.2011Renewal fee patent year 03
14.11.2011Renewal fee patent year 04
14.11.2011Renewal fee patent year 05
14.11.2011Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.07.201207   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]  - PROUS J R ET AL, "Annual update 2004/2005 - Treatment of musculoskeletal disorders", DRUGS OF THE FUTURE, (200502), vol. 30, no. 2, ISSN 0377-8282, pages 181 - 232, XP002425829 [X] 1-14 * page 223 * * page 206, column 1, paragraph L - column 2, paragraph 1 * * page 229, column 2, paragraph L - page 230, column 1, paragraph 1 *
 [X]  - BARONE D ET AL, "Prolonged depletion of circulating B cells in cynomolgus monkeys after a single dose of TRU-015, a novel CD20 directed therapeutic", ANNALS OF THE RHEUMATIC DISEASES, & ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY; VIENNA, AUSTRIA; JUNE 08 11, 2005, (20050701), vol. 64, no. Suppl. 3, ISSN 0003-4967, pages 159 - 160, XP008075207 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1136/ard.2003.020297
 [X]  - BARONE D ET AL, "TRU-015, a novel CD20-directed biologic therapy, demonstrates significant anti-tumor activity in human tumor xenograft models", JOURNAL OF CLINICAL ONCOLOGY, (20050601), vol. 23, no. 16-part1-Supp, pages 178S - 178S, XP009080866 [X] 1-14 * abstract *
 [X]  - RASTETTER W ET AL, "RITUXIMAB: EXPANDING ROLE IN THERAPY FOR LYMPHOMAS AND AUTOIMMUNE DISEASES", ANNUAL REVIEW OF MEDICINE : SELECTED TOPICS IN THE CLINICAL SCIENCES, ANNUAL REVIEWS INC., PALO ALTO, CA, US, (2004), vol. 55, ISSN 0066-4219, pages 477 - 503, XP008060326 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1146/annurev.med.55.091902.104249
 [X]  - PAPADAKIS K ET AL, "Anti-CD20 chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, US, (200302), vol. 124, no. 2, ISSN 0016-5085, page 583, XP002392206 [X] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1053/gast.2003.50081
 [XD]  - LEVINE TODD D, "Rituximab in the treatment of dermatomyositism - An opel-label pilot study", ARTHRITIS & RHEUMATISM, (200502), vol. 52, no. 2, ISSN 0004-3591, pages 601 - 607, XP002425830 [XD] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1002/art.20849
 [XD]  - CAMBRIDGE GERALDINE ET AL, "Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM AUG 2003, (200308), vol. 48, no. 8, ISSN 0004-3591, pages 2146 - 2154, XP002425831 [XD] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1002/art.11181
 [X]  - CREE BRUCE ET AL, "Tolerability and effects of Rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS)", NEUROLOGY, & 56TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; SAN FRANCISCO, CA, USA; APRIL 24 -MAY 01, 2004, (200404), vol. 62, no. 7, Suppl. 5, ISSN 0028-3878, page A492, XP009080814 [X] 1-17 * abstract *
by applicantUS4861579
 EP0330191
 EP0332865
 WO9503770
 US5500362
 US5595721
 US5677180
 US5721108
 US5736137
 US5776456
 US5843439
 US5843398
 US5849898
 WO9856418
 WO9858964
 US5888773
 WO9922764
 WO9951642
 US6016542
 WO0009160
 WO0020864
 WO0027428
 WO0027433
 US6090365
 WO0042072
 WO0044788
 US6120767
 WO0067796
 WO0067795
 WO0074718
 WO0076542
 US6171586
 WO0103734
 WO0110462
 WO0110461
 WO0110460
 US6194551
 WO0113945
 US6224866
 US6242195
 US6287537
 WO0172333
 WO0174388
 WO0177342
 WO0180884
 WO0197858
 US2002004587
 US2002006404
 WO0204021
 US2002009444
 US2002012665
 US6368596
 US2002041847
 WO0234790
 US6399061
 US6410391
 WO02056910
 WO02060955
 US2002128488
 US6455043
 WO02079255
 WO02096948
 US2002197255
 US2002197256
 WO02102312
 US2003021781
 US2003026801
 US6528624
 US6538124
 US2003118592
 US2003133939
 WO2005017148
 WO2005037989
 US2005136049
    - SHLOMCHIK ET AL., J EXP. MED., (1994), vol. 180, pages 1295 - 306
    - CHAN ET AL., J EXP. MED, (1999), vol. 189, pages 1639 - 48
    - EINFELD ET AL., EMBO J., (1988), vol. 7, pages 711 - 17
    - CLARK ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 4494 - 98
    - SHAN ET AL., BLOOD, (1998), vol. 91, pages 1644 - 52
    - DEANS ET AL., J. LMMUNOL., (1993), vol. 146, pages 846 - 53
    - FUNAKOSHI, J. IMMUNOTHERAPY, (1996), vol. 19, pages 93 - 101
    - EINFELD ET AL., EMBO J, (1988), vol. 7, pages 711 - 17
    - STAMENKOVIC, J . EXP. MED., (1983), vol. 167, pages 1975 - 80
    - TEDDER ET AL., J. IMMUNOL., (1988), vol. 141, pages 4388 - 4394
    - PRESS ET AL., BLOOD, (1987), vol. 69, pages 584 - 91
    - REFF ET AL., BLOOD, (1994), vol. 83
    - ENDO, GAN TO KAGAKU RYOHO, (1999), vol. 26, pages 744 - 748
    - LIU ET AL., J. LMMUNOL., (1987), vol. 139, pages 3521 - 26
    - MCLAUGHLIN ET AL., ONCOLOGY, (1998), vol. 12, pages 1763 - 1777
    - LEGET ET AL., CURR. OPIN. ONCOL., (1998), vol. 10, pages 548 - 551
    - WHITE ET AL., PHARM. SCI. TECHNOL. TODAY, (1999), vol. 2, pages 95 - 101
    - NGUYEN ET AL., EUR J HAEMATOL., (1999), vol. 62, pages 76 - 82
    - LIN ET AL., SEM ONCOL., (2003), vol. 30, pages 483 - 92
    - EDWARDS, N ENGL J MED., (2004), vol. 350, pages 2546 - 8
    - CAMBRIDGE ET AL., ARTHRITIS RHEUM., (2003), vol. 48, pages 2146 - 54
    - LEANDRO ET AL., ARTHRITIS RHEUM., (2002), vol. 46, pages 2673 - 7
    - LOONEY ET AL., ARTHRITIS RHEUM., (2004), vol. 50, pages 2580 - 9
    - TREON ET AL., IMMUNOTHER, (2001), vol. 24, pages 272 - 9
    - MONSON ET AL., ARCH NEUROL., (2005), vol. 62, pages 258 - 64
    - STASHI ET AL., "Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura", BLOOD, (2001), vol. 98, pages 952 - 957
    - LEANDRO ET AL., "Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion", ANN RHEUM DIS, (2002), vol. 61, pages 833 - 888
    - LEANDRO ET AL., "Lymphocyte depletion in rheumatoid arthritis: early evidence for safety, efficacy and dose response", ARTHRITIS AND RHEUMATISM, (2001), vol. 44, page 370
    - LEANDRO ET AL., "An open study of B lymphocyte depletion in systemic lupus erythematosus", ARTHRITIS RHEUM., (2002), vol. 46, doi:doi:10.1002/art.10541, pages 2673 - 2677, XP002378313

DOI:   http://dx.doi.org/10.1002/art.10541
    - EDWARDS ET AL., "Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes", RHEUMATOLOGY, (2001), vol. 40, doi:doi:10.1093/rheumatology/40.2.205, pages 205 - 211, XP002348931

DOI:   http://dx.doi.org/10.1093/rheumatology/40.2.205
    - EDWARDS ET AL., "B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders", BIOCHEM. SOC. TRANS., (2002), vol. 30, doi:doi:10.1042/BST0300824, pages 824 - 828, XP002306250

DOI:   http://dx.doi.org/10.1042/BST0300824
    - EDWARDS ET AL., "Efficacy and safety of Rituximab, a B-cell targeted chimeric monoclonal antibody: A randomized, placebo controlled trial in patients with rheumatoid arthritis", ARTHRITIS RHEUM., (2002), vol. 46, page 197
    - LEVINE ET AL., "IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab", NEUROLOGY, (1999), vol. 52, pages 1701 - 1704, XP000942610
    - DEVITA ET AL., "Efficacy of selective B-cell blockade in the treatment of rheumatoid arthritis", ARTHRITIS RHEUM., (2002), vol. 46, pages 2029 - 2033
    - MALONEY ET AL., BLOOD, (1997), vol. 90, pages 2188 - 2195
    - MALONEY ET AL., BLOOD, (1994), vol. 84, pages 2457 - 2466
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 83
    - YOKOTA ET AL., CANCER RES., (1992), vol. 52, pages 3402 - 08
    - CHAUDARY ET AL., NATURE, (1989), vol. 339, page 394
    - BATRA ET AL., MOL. CELL. BIOL., (1991), vol. 11, page 2200
    - DAVIS ET AL., J BIOL. CHEM., (1990), vol. 265, pages 10410 - 18
    - TRAUNECKER ET AL., EMBO J, (1991), vol. 10, pages 3655 - 59
    - JOST ET AL., J. BIOL. CHEM., (1994), vol. 69, pages 26267 - 73
    - CHAUDATY, NATURE, (1989), vol. 339, page 394
    - BEST ET AL., "Development of a Crohn's disease activity index", GASTROENTEROLOGY, (1976), vol. 70, pages 439 - 444, XP008063076
    - MILLER, RHEUM DIS CLIN NORTH AM., (1994), vol. 20, pages 811 - 826
    - TARGOFF, CURR PROBL DERMATOL, (1991), vol. 3, pages 131 - 180
    - GOTTDIENER ET AL., AM J CARDIOL., (1978), vol. 41, pages 1141 - 49
    - SCATCHARD ET AL., ANN. N.Y. ACAD. SCI., (1949), vol. 51, page 660
    - FIX, J. PHARM. SCI., (1996), vol. 85, pages 1282 - 1285
    - OLIYAI, STELLA, ANN. REV. PHARMACOL. TOXICOL., (1993), vol. 32, pages 521 - 544
    - DONG ET AL., "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", NAT. MED., (1999), vol. 5, doi:doi:10.1038/70932, pages 1365 - 1369, XP002942544

DOI:   http://dx.doi.org/10.1038/70932
    - FELSON ET AL., ARTHRITIS RHEUM., (1995), vol. 38, pages 727 - 35
    - SIMONIS ET AL., SCAND. J GASTROENT., (1998), vol. 33, pages 283 - 8
    - RIDER ET AL., ARTHRITIS RHEUM., (2004), vol. 50, pages 2281 - 90
    - GLADMAN ET AL., J RHEUMATOL, (1994), vol. 21, pages 1468 - 71
    - TAN ET AL., ARTHRITIS RHEUM., (1982), vol. 25, pages 1271 - 7
    - PETRI ET AL., ARTHRITIS RHEUM., (2004), vol. 50, pages 2858 - 68
    - KURTZKE, F., NEUROLOGY, (1983), vol. 33, pages 1444 - 52
    - RUDICK ET AL., NEUROLOGY, (1997), vol. 49, pages 358 - 63
    - "The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma", N ENGL J MED., (1993), vol. 329, pages 987 - 94
    - "The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-HodgRin's lymphoma", NEW ENGLAND J. MED., (1993), vol. 329, pages 987 - 994
    - CHESON ET AL., J Clin Oncol., NATIONAL CANCER INSTITUTE, (1999), vol. 17, page 1244
    - GRILLO-LOPEZ ET AL., ANN ONCOL, (2000), vol. 11, pages 399 - 408
    - CHESON ET AL., CLIN ADV HEMATOL ONCOL., (2006), vol. 4, pages 4 - 5
    - CHESON ET AL., J CLIN ONCOL., (2003), vol. 21, pages 4642 - 9
    - CHESON ET AL., BLOOD, (2000), vol. 96, pages 3671 - 4
    - VAN DER KOLK, BR. J HAEMATOL., (2001), vol. 115, pages 807 - 11
    - GAZZANO-SANTORO ET AL., J IMMUNOL. METH., (1997), vol. 202, pages 163 - 71
    - MILLER, Arthritis and Allied Conditions: A Textbook of Rheumatology, (2005), page 1614
    - LEVINE, ARTHRITIS RHEUM., (2005), vol. 52, pages 601 - 607
    - RIDER, ARTHRITIS RHEUM., (2004), vol. 50, pages 2281 - 90
    - TAKEMURA ET AL., J LMMUNOL., (2001), vol. 167, pages 1072 - 80
 US20030627556
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.